NEW YORK (GenomeWeb News) – Illumina said today that its noninvasive prenatal testing subsidiary Verinata Health has signed an exclusive agreement with Teva Pharmaceutical Industries to commercialize its Verifi test in Israel.

Under the terms of the five-year agreement, Teva will be the exclusive distributor of Verifi in Israel. All tests will be run in Verinata's CLIA-certified laboratory in California, while Israel's Clalit Health Services will provide reimbursement for Verifi through supplemental insurance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.